Luven is a unique cancer diagnostic technology that is designed to save millions of lives. Luven technology permits to detect the disease in the early stage and prevents its progression in thousands of patients. It prevents its progression in thousands of patients. Luven technology allows doctors to detect the disease in the early stages
It is unique technology which differentiates between chronic inflammatory conditions and cancer. The diagnostic techniques include paracentesis test.
Allocation of Funds
Our sales target
At the preICO stage - 3 000 000 tokens (1st day bonus – 30%, 1st-week bonus – 25%, 2nd week bonus – 20%, 3d week bonus – 15%)
At the ICO stage - 27 000 000 (1st week – 10%, 1 to 1 onwards)
9,000,000 tokens will be kept by the founders and developers of Luven Diagnostic.
Bonuses will be also awarded for the investment volume
>= 5,000 ETH 5%
>= 3,000 ETH 4%
>= 1,000 ETH 3%
>= 100 ETH 2%
>= 3 ETH 1%
Token standard: ERC20.
Rate: 1$ = 1 LVN
Participation in ICO is possible both with Ethereum and Bitcoin.
Alexander Danilchenko - CEO
Nikolay Shchukin - Postgraduate Student of Chair for Biomedical Engineering
Aleksander Shchukin - Nuclear physicist
Galina Shchukina - Geneticist & Cytologist
Grigory Evglevskiy - CTO
Alexander Kamensky - Principal Software Engineer
Yana Ivchenko - PR Manager
Lina Lisitsa - SMO/SMM Manager
Eugene Chernogubov - Early investor